相关临床试验
16
0 进行中
药物批准
3
批准总数
监管机构
2
监管机构数
成立时间
1953
已完成
7
43.8%
终止
1
6.3%
撤回
8
50.0%
- Nanobiotix announced first data from the CONVERGE Phase 2 trial evaluating JNJ-1900 (NBTXR3) in stage 3 inoperable non-small cell lung cancer, showing a 71.4% objective response rate compared to an estimated benchmark of 45-50%. - The novel hafnium oxide nanoparticle radioenhancer demonstrated an acceptable safety profile with no serious treatment-emergent adverse events and 100% disease control rate in the initial seven patients evaluated. - The company strengthened its financial position through a $71 million royalty financing agreement with HealthCare Royalty, extending its cash runway into early 2028 while advancing multiple clinical programs across solid tumor types.
- Dr. Reddy's Laboratories is strategically positioning three key launches—semaglutide in Canada, denosumab in the U.S. and Europe, and biosimilar abatacept—to offset declining revenues from generic Revlimid as its exclusivity period ends. - The company reported Q2 FY26 consolidated revenues of ₹8,805 crore, up 9.8% year-on-year, but faces margin pressure with gross margins moderating to 54.7% due to lower gRevlimid sales and U.S. price erosion. - Semaglutide awaits regulatory clearance in Canada with plans for launch in 87 countries, while denosumab has received positive opinion from European regulators with expected approval by December 2025. - Despite near-term headwinds from Revlimid's declining contribution, the company maintains confidence in achieving single-digit U.S. growth over a two-to-three-year horizon through its diversified pipeline and strategic investments.
- Contineum Therapeutics has completed enrollment of 168 patients in its Phase 2 VISTA trial evaluating PIPE-307 for relapsing-remitting multiple sclerosis (RRMS). - PIPE-307, a potentially first-in-class M1 receptor antagonist, aims to promote remyelination in RRMS patients by modulating oligodendrocyte precursor cell differentiation. - The randomized, double-blind, placebo-controlled trial will assess the safety and efficacy of PIPE-307, with topline data expected in the third quarter of 2025. - The VISTA trial is designed to measure clinical and imaging endpoints sensitive to changes in remyelination, potentially marking a new treatment approach for RRMS.
